Denver Multiple Myeloma Rounds

Dr.Forsberg received his bachelor’s degree from Washington University in St.Louis. He completed medical school at the University of Colorado School ofMedicine. He went to New York for his medical training and completed hisresidency in Internal Medicine at the Weill-Cornell Medical College/NewYork-Presbyterian Hospital. He served as chief medical resident at MemorialSloan Kettering Cancer Center before returning to Cornell for his fellowshiptraining in Hematology and Medical Oncology. In 2016 he returned to Colorado tojoin the blood cancer and BMT program at the University of Colorado.

Dr.Forsberg’s clinical and research focus centers on multiple myeloma and relateddiseases including amyloidosis and Waldenstrom’s Macroglobulinemia. He servesas the principle investigator on various clinical trials. He has published andpresented his work at the national and international level.

Tara Gregory, MD, is a Member Physician at the Colorado Blood Cancer Institute and part of the Plasma Cell Disease Group. Dr. Gregory joined CBCI in 2009 and is board certified in internal medicine and medical oncology. Dr. Gregory earned her Bachelor of Arts summa cum laude in Hispanic Linguistics and her honors thesis focused on the critical age of learning and brain plasticity. She is fluent in Spanish. She also received her Bachelor of Science in molecular and cellular biology summa cum laude and wrote her honors thesis on the expression of iNOS in mouse cardiac transplant grafts.

Dr. Gregory was born and raised in Scottsdale, Arizona. Her father was a physician, giving her an early exposure to a career in healthcare. She graduated from the University of Arizona School of Medicine in Tucson, Arizona and did a residency in internal medicine at the Banner Good Samaritan/Carl T. Hayden VAMC program. Dr. Gregory then moved to Denver, Colorado to complete her medical oncology fellowship at the University of Colorado. After finishing fellowship, Dr. Gregory was the first blood and marrow transplant fellow at CBCI and has since joined the program as a BMT physician. She has been recognized by the house staff for excellence and dedication to teaching.

Dr. Gregory is the co-director of the Plasma Cell Dyscrasia Program at CBCI focusing on diseases such as multiple myeloma, amyloidosis, monoclonal gammopathies and plasma cell leukemia. The focus of her research work is in multiple myeloma treatments including chimeric antigen T cell therapy. She is a member of the International Myeloma Society. In addition to her research publications and presentations at national meetings, Dr. Gregory has been accepted to the American Society of Transplant and Cellular Therapies National Leadership Program.

Dr. Gregory is passionate about educating patients to ensure they understand their disease and working in partnership with patients to make treatment decisions that honor quality of life as well as outcomes. Dr. Gregory is a member of several societies, including the American Society of Hematology, the American Society of Clinical Oncology and the American Society for Blood and Marrow Transplantation. Dr. Gregory participates in clinical trials including research in blood and marrow transplant outcomes, the results which have been presented at multiple research meetings. Dr. Gregory lives in Denver with her wonderful family and dogs and enjoys exercising at Orangetheory Fitness as well as recreating at her Salida home with hiking, skiing and family time.

Jeffrey Matous, MD, is a Member Physician at the Colorado Blood Cancer Institute and part of the Plasma Cell Diseases Group. Dr. Matous became a member of CBCI in 2010. He is presently a clinical professor of medicine at the University of Colorado Health Sciences Center. Dr. Matous is also on the board of the Leukemia-Lymphoma Society.

Dr. Matous was born in Sarnia, Ontario, Canada but raised in Seattle, Washington. Dr. Matous received his medical degree with honors from the University of Washington. He completed his internal medicine residency and chief residency at the University of Colorado Health Sciences Center. His fellowship training in hematology and bone marrow transplantation was completed at the University of Washington and the Fred Hutchinson Cancer Research Center. He returned to Denver to practice at Rocky Mountain Cancer Centers in 1994, where he worked until 2010 before moving to CBCI.

Dr. Matous specializes in the treatment of blood cancers such as multiple myeloma, Waldenstrom Macroglobulinemia and amyloidosis as well as in the field of blood & marrow transplantation. Dr. Matous has a particular interest in medical education and supervises both medical students and internal medicine residents who are interested in the field of hematology/oncology. Dr. Matous has been recognized as an outstanding clinical teacher of the medicine house staff. He is the lead investigator in clinical trials in the areas of Waldenstrom’s Macroglobulinemia, multiple myeloma, and amyloidosis, and has been recognized by his peers as Top Doctor for the past 16 years. He is passionate about educating patients with these diseases.

Dr. Matous is married with three adult children. Outside of work he enjoys cycling, languages, and our nation’s pastime.

Henning Schade, MD is an Assistant Member Physician at the Colorado Blood Cancer Institute and part of the Plasma Cell and Lymphoid Disease Groups. Dr. Schade completed his Bone Marrow Transplant Fellowship Program at CBCI in 2017 and joined immediately afterward. Dr. Schade is board certified in Internal Medicine and Oncology and has focused his training in Bone Marrow Transplantation and Malignant Hematology.

Dr. Schade was born and raised in Hesse, Germany. He stayed in his hometown near Frankfurt/Main until completion of high school when he decided to join a Catholic church group for a mandatory civilian service. Henning has been dedicated to patient care since he started working with patients and elderly with special needs during this period of civilian service. This inspired him to join nursing school for a 3-year training to become licensed nurse.

Soon after he finished nursing school in 1998, he signed up for medical school training. He continued to work as a part-time nurse during this time. After finishing med school in 2006 he joined UK-S-H in Kiel, Germany to initiate training as an internal medicine resident and BMT trainee at the bone marrow transplantation center at MSH Kiel. He stayed there until 2010 when he decided to move to the US to continue training as a physician. Dr. Schade then finished a residency in internal medicine in 2014 at MUSC in Charleston South Carolina. He then joined University of Colorado/Anschutz for a Hematology/Oncology Fellowship. After completion in 2016, he joined Colorado Blood Cancer Institute for dedicated BMT fellowship year.

Dr. Schade has published several scientific articles, abstracts and posters at ASCO, ASH and EBMT, including his doctoral thesis about second allogeneic stem cell transplantation in patients with relapsed hematologic malignancy. During his time as an internal medicine resident at MUSC he worked in Dr. Yubin Kang’s lab on Multiple Myeloma cell lines and became interested in translational research. During his fellowship in Hematology/Oncology at the University of Colorado he worked in Brent Palmer’s lab and studied PD-1 expression on CD4+ T cells and CMV+ T cells after allogenic stem cell transplantation. The results were published in BBMT in 08/2016. These findings were the fundamental basis for his upcoming research projects.

Dr. Schade’s research interest is primarily in the treatment of plasma cell and lymphoid diseases. He is the primary investigator for several clinical studies that investigate novel treatment options for patients with Multiple Myeloma and Hodgkin lymphoma. He also has a strong research interest in immune reconstitution after autologous and allogenic stem cell transplantation and has published his research in journals such as BBMT. At The Colorado Blood Cancer Institute he developed an investigator initiated a phase 1 protocol for patients with chemotherapy-refractory AML/MDS using GVHD prophylaxis with posttransplant cyclophosphamide followed by PD-1 inhibition with Nivolumab for consolidation. This protocol now offers a potentially curative treatment option for patients that otherwise would not meet criteria to undergo allogenic stem cell transplantation.

Dr. Schade loves to bake all kinds of goodies including sourdough bread, bagels and New York style pizza. He also loves to go fishing with his kids. He loves the outdoors and can be found in the mountains hiking and skiing with his family. Dr. Schade is an enthusiastic fan of the Denver Nuggets and he of course is a big fan of European soccer.